Estados Unidos · Bolsa y Finanzas · Yahoo Finance

AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

Publicado por Yahoo Finance · Estados Unidos hace 8 h

AnnJi Pharmaceutical Co., Ltd. (AnnJi, TPEx: 7754), a clinical-stage drug development company focused on innovative small molecules, today announced that it is proceeding with the…

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

También te puede interesar

Japan’s PMI data signals cooling momentum across manufacturing and services

Joint venture of OKX and NYSE parent ICE files for 24/7 tokenized U.S. stock trading

Russia hospitalizes almost 200 people after researcher's death from plague: reports

After 11 years on an H-1B visa, I still miss my family back home. Here’s why I stay in the US.

Zcash activates NU7 on testnet ahead of November mainnet target

Sam Altman says 'the world should accept some bad things happening for the benefits' of AI

AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

Compartir

También te puede interesar

Japan’s PMI data signals cooling momentum across manufacturing and services

Joint venture of OKX and NYSE parent ICE files for 24/7 tokenized U.S. stock trading

Russia hospitalizes almost 200 people after researcher's death from plague: reports

After 11 years on an H-1B visa, I still miss my family back home. Here’s why I stay in the US.

Zcash activates NU7 on testnet ahead of November mainnet target

Sam Altman says 'the world should accept some bad things happening for the benefits' of AI